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Abstract
Background: Therapeutic plasma exchange (TPE) is used increasingly in small animals to
remove circulating large molecular products such as antibodies, pathogenic proteins, and
protein-bound toxins. Specific, efficient, and safe protocols need to be developed.
Hypothesis/Objectives: To describe the technique of membrane-based TPE, the
resulting physiological and metabolic changes, and to define an adequate regional cit-
rate anticoagulation protocol.
Animals: Thirty-four dogs treated with TPE (2011-2017).
Methods: Retrospective review of all TPE treatments performed at the Vetsuisse
Faculty, University of Bern, identified through a search of the institutional database
for extracorporeal treatments.
Results: Sixty-four treatments were performed, resulting in 1.0 plasma volume exchange
(range, 0.4-1.1). Replacement fluids included fresh frozen plasma (12%-100% volume),
colloids (0%-52%), human albumin (0%-41%), and saline (0%-70%). Anticoagulation was
performed with regional citrate (n = 24), systemic heparinization (n = 2), or combined
(n = 38). Main relevant laboratory changes included a 24.7% decrease in total proteins
(interquartile range, 16.7-31.4; P < .001), 53% in fibrinogen (−30 to 63; P = .009), 36%
in bilirubin (13-43, P = .02), 9.0% in urea (0.7-15.7; P < .001), and 4.5% in creatinine
(−6.6 to 10.6; P = .006). Citrate accumulation was evidenced in all dogs, more pro-
nounced in those with renal but not with hepatic impairment. Maximal tolerable
citrate rates were estimated as 5.5 and 9.0 μmol/kg/min for treatments in dogs with
andwithout renal impairment, respectively. Complications were observed in 22 treat-
ments (34%) and were fatal in 2 dogs.
Conclusions and Clinical Importance: Therapeutic plasma exchange causes metabolic
and biochemical alterations. Understanding these effects makes possible to anticipate
most complications and to improve safety of the procedure.
K E YWORD S
coagulation, extracorporeal blood purification, plasmapheresis
Abbreviations: AKI, acute kidney injury; BW, body weight; cTPE, centrifugation-based therapeutic plasma exchange; FFP, fresh-frozen plasma; HAlb, human albumin; HepCit, heparin-citrate
anticoagulation; HES, hydroxyethylstarch; iCa, ionized calcium; IQR, interquartile range; mTPE, membrane-based therapeutic plasma exchange; niCa, non-ionized calcium; PVE, plasma
volume exchange; RCA, regional citrate anticoagulation; ROC, receiver operating characteristic; SH, systemic heparinization; TCa, total calcium; TCa:iCa, total calcium to ionized calcium ratio;
TPE, therapeutic plasma exchange.
Received: 17 September 2018 Accepted: 9 May 2019
DOI: 10.1111/jvim.15528
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
J Vet Intern Med. 2019;1–11. wileyonlinelibrary.com/journal/jvim 1
1 | INTRODUCTION
Therapeutic plasma exchange (TPE) is an extracorporeal blood
purification technique aiming at removing large molecular weight
compounds from the circulation.1 Main indications include
immune-mediated diseases, hyperviscosity syndrome and toxico-
sis caused by highly protein-bound solutes.2 Aside from the older
manual centrifugation, 2 main modern techniques have been
developed to separate the plasma from the blood circulating in
an extracorporeal circuit: continuous flow centrifugation-based
TPE (cTPE) and membrane filtration TPE (mTPE).1,3 Although the
cTPE platforms offer the possibility of other apheresis techniques
such as red cell, white cell, or platelet apheresis, they require
specific machines that are only available in few specialized institu-
tions. The technique of mTPE, however, has become more widely
available, with the development of multifunctional blood purifica-
tion platforms, allowing a wide spectrum of organ replacement
treatments including renal, liver, or pulmonary support. Safe extracor-
poreal treatments require a good understanding of the physiological,
hematological, and biochemical changes expected from the treatments.
Although most treatments are initially inspired by human protocols,
extrapolation to dogs and cats with their diseases and their specific
pathophysiological, cardiovascular, and metabolic responses has limita-
tions. Small animal protocols therefore need to be established based
on species-specific data, but few cases have been published, reporting
its use in toxicoses,4-6 hyperviscosity syndromes,7-11 immune-mediated
diseases,12-17 and microangiopathy.18
The mTPE technique uses a continuous extracorporeal circula-
tion and a hollow-fiber plasma separator with a large pore high cut-
off membrane retaining only the cellular blood elements and filtering
out the plasma. Replacement fluids are used for isovolemic reconsti-
tution of the blood and for compensation of the discarded plasma
components. Fresh-frozen plasma (FFP) typically is the first-choice
replacement, but most TPE indications do not require 100% FFP and
some of the plasma can be replaced by albumin, colloids, or crystal-
loids, depending on the underlying disease.
For animals at risk of bleeding, systemic heparinization (SH) can
be replaced by regional citrate anticoagulation (RCA) for extracor-
poreal blood purification techniques.19 However, the clearance of
solutes in mTPE being limited by a maximal filtration fraction of
20%-25%, citrate and citrate-calcium complexes tend to accumu-
late when their administration rate exceeds the capacity of hepatic
metabolism. The resulting citrate toxicosis can lead to ionized
hypocalcemia, total hypercalcemia, and metabolic alkalosis, limiting
the blood flow rate and the substitution rate with citrate-containing
FFP. Therefore, RCA is considered relatively contraindicated for
mTPE in humans.20,21 For diseases with hemostatic disorders
including thrombocytopenia, disseminated intravascular coagula-
tion, pulmonary hemorrhages, or central nervous system bleeding,
SH remains an absolute contraindication and RCA has been used
tentatively at low administration rates. Data on citrate tolerance in
TPE treatments for dogs are therefore needed to improve the
safety of the procedure and to widen the spectrum of treatable
conditions.
The aims of this retrospective study were therefore to describe
the technique of mTPE as used in our hospital and to analyze the
clinical and clinicopathological changes associated with the treat-
ment. The tolerance to citrate administration during mTPE was
analyzed to define a tentative and potentially safe administration
rate for dogs.
2 | MATERIALS AND METHODS
2.1 | Study design and animals
This study was designed as a retrospective evaluation of data collected
from treatments based on prospectively planned protocols. Dogs
treated with mTPE between 2011 and 2017 were included in the analy-
sis. Their medical and treatment records were analyzed and following
data were extracted: signalment, disease and indication for mTPE treat-
ment, vascular access, treatment prescription, clinicopathological data
before and after treatment, and specifics of anticoagulation.
2.2 | Specifics of mTPE treatment
Vascular access was provided using a right jugular central venous
catheter adapted to the size of the dog and dedicated strictly to
the blood purification procedure. Between the individual treatments,
the access catheter was locked either with sodium citrate (46.7%,
DuraLockc, Medcomp, Euromed Swiss AG, Frauenfeld, Switzerland)
or with unfractionated heparin (50-1000 IU/mL, Heparin Bichsel, Dr
G. Bichsel Pharmacy, Interlaken, Switzerland).
The mTPE treatment was performed on a Prismaflex platform,
using a TPE 1000 circuit (Baxter Healthcare, Glattpark, Switzerland).
This pre-connected set has a total priming blood volume of 71 mL.
The incorporated plasmafilter with a polypropylene membrane has a
blood volume of 23 mL and an effective filtration surface area of
0.15 m2. Its sieving coefficient for albumin is 0.97, for IgG 1.00, and
for IgM 0.92 (manufacturer's data). Treatments were prescribed
based on human protocols and were adjusted individually
depending on the actual requirements of the animals, the perceived
complication risks, and the response to previous treatments. The
basis for the calculation of the mTPE prescription was to provide
1.0 plasma volume exchange (PVE) per treatment. Plasma volume
was estimated using the formula: PVE = 0.08 × body weight
(BW) × (1 − hematocrit), assuming a blood volume of 8% of the BW.
Replacement fluids included FFP, 5% human albumin (HAlb, as
a 1:3 mixture of 20% HAlb [Albumin CSL 20%, CSL Behring, Bern,
Switzerland] and 0.9% NaCl), 3% hydroxyethylstarch (HES, as a 1:1
mixture of 6% HES [Voluven balanced 6%, 130/0.4, Fresenius Kabi,
Oberdorf, Switzerland] and 0.9% NaCl), and 0.9% saline. The basic
composition of the replacement fluid consisted of 35%-65% FFP,
10%-30% HAlb, 0%-10% HES, and 0%-50% saline, administered
sequentially; it was adjusted to the individual needs of the animals,
taking in consideration the underlying disease and comorbid
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disorders, the cardiovascular condition, and the hemostatic status.
The plasma was preferentially chosen from the same blood group
as the dogs, but this could not always be done because of limited
availability concerns. Intravenous test injections of 1 mL HAlb and
of 1 mL of each unit FFP were performed sequentially, at a
15 minute interval, immediately before the mTPE was initiated.
Specific monitoring was implemented for 14 days to evaluate for
potential adverse effects of the administration of HAlb and HES. Daily
physical examinations were performed with special attention to body
temperature, peripheral and facial edema, skin lesions suggestive of
vasculitis, and gastro-intestinal and respiratory disturbances. Complete
blood counts and chemistry profiles were performed every 2-5 days
during hospitalization, and the presence of proteinuria was assessed
when clinical or laboratory signs potentially associated with glomerular
disease were observed.
Anticoagulation consisted of either SH, RCA, or a combination of
both (heparin-citrate anticoagulation [HepCit]), depending on the per-
ceived risk of hemorrhage or of thrombosis from the underlying dis-
ease. For SH, 50 IU/kg of unfractionated heparin (Heparin Bichsel,
1000 U/mL, Dr Bichsel Pharmacy, Interlaken, Switzerland) were
administered IV 5 minutes before starting treatment and a constant
rate infusion of 50 IU/kg/h was maintained until 15 minutes before
the end of the treatment. Monitoring and adjustments were based on
the activated coagulation time (Medtronic ACT II Automated Coagula-
tion Timer, Medtronic Switzerland, Munchenbuchsee, Switzerland)
maintained between 150 and 200 seconds (reference range,
60-90 seconds). For RCA, the anticoagulation module of the Pris-
maflex platform was used with minor adjustments, based on the pro-
tocol recently described for intermittent hemodialysis in dogs.19
Trisodium citrate 3% (Dr Bichsel Pharmacy, Interlaken, Switzerland)
was administered at an initial flow rate providing 3.5 mmol citrate per
liter of blood; calcium chloride dihydrate 5% (Dr Bichsel Pharmacy,
Interlaken, Switzerland) was administered with an external syringe pump
at an initial flow rate corresponding to 1/10 of the citrate flow rate
(0.33 mmol Ca per mmol citrate). Rate adjustments were based on ion-
ized calcium (iCa) monitoring in the dog (goal, 1.0-1.2 mmol/L) and in
the circuit (goal, <0.3 mmol/L) at 30 minutes of treatment start and
every 30-60 minutes thereafter. For HepCit anticoagulation, the same
RCA protocol was used, and in addition, a low dose of unfractionated
heparin (10-20 IU/kg) was administered IV at the start of treatment; this
injection was repeated if deemed necessary based on changes in the fil-
ter pressure gradient and in the transmembrane pressure. In these dogs,
the monitoring of anticoagulation was based solely on the monitoring of
the iCa, as for pure RCA.
As the most appropriate variables and cutoff values to define cit-
rate toxicosis have not yet been evaluated in dogs, a 3-step grading
system (nonrelevant, mild, severe accumulation) was used, based on a
combination of all 4 variables, with cutoff values similar to those used
in humans22-25: decreased iCa by >0.2 mmol/L (mild) or >0.3 mmol/L
(severe); increased non-ionized calcium (niCa) by >1.0 mmol/L (mild)
or >1.5 mmol/L (severe); increased total calcium (TCa) by >1 mmol/L
(mild) or >1.5 mmol/L (severe); and increased total calcium to ionized
calcium (TCa:iCa) ratio by >1 (mild) or >2 (severe). Mild citrate
accumulation was defined as the presence of at least 2/4 abnormal
variables in the mild range and severe toxicosis by the presence of at
least 2/4 abnormal variables in the severe range.
2.3 | Data analysis and statistical methods
Data analysis is mostly descriptive. To evaluate the significance of
the laboratory changes associated with the treatments, compari-
sons before and after treatment were however analyzed statisti-
cally, if data were available for more than half of the treatments.
For the analysis of citrate accumulation and its occurrence, the dog
population was stratified as renal versus nonrenal (creatinine cut-
off, 1.3 mg/dL, 117 μmol/L) and hepatic versus non-hepatic (biliru-
bin cutoff, 1.2 mg/dL, 20 μmol/L).
As most numerical data sets were not normally distributed, they are
presented as median and interquartile range (IQR) and analyzed using
nonparametric methods. For comparison of numerical data between
groups, a Wilcoxon signed-rank test was used for paired data, a Mann-
Whitney U Test for unpaired data, and a Kruskal-Wallis 1-way ANOVA
for comparison of more than 2 groups. A chi-square test or a Fisher
exact test was used for comparison of proportions. Odds ratios for
development of citrate accumulation were calculated for dogs affected
with renal or hepatic dysfunction, compared to their non-affected
counterparts. A receiver-operating characteristics (ROC) curve analysis
was used to determine a tentative cutoff in citrate administration
predicting a 20%-risk of severe citrate accumulation, a risk considered
arbitrarily acceptable for this type of treatment. A P-value <.05 was
considered significant. Analyses were performed with the NCSS com-
mercial statistical software (NCSS 9.0.15; NCSS, LLC, Kaysville, Utah).
3 | RESULTS
3.1 | Animals and diseases
Thirty-four dogs were treated with mTPE, including 19 males (12 intact,
35%; 7 castrated, 21%) and 15 females (5 intact, 15%; 10 spayed, 29%).
Thirty-two dogs were pure-bred dogs from 26 different breeds, and
2 were mixed-breed dogs. Represented breeds included Labrador
Retriever (n = 3), Poodle (n = 3), Shi-Tzu (n = 2), Yorkshire Terrier (n = 2),
and 22 further breeds with 1 dog each. Median age was 5.2 years (IQR,
2.5-8.5) and BWwas 13.0 kg (IQR, 8.2-29.3; range, 3.3-45.0).
Main indications for mTPE were primary or secondary immune
diseases in 29 dogs (immune-mediated hemolytic anemia, n = 13;
immune-mediated thrombocytopenia, n = 9; leptospirosis-associated
pulmonary hemorrhages, n = 13; and neuromuscular diseases, n = 2).
Other indications included polysystemic diseases in 5 dogs (sepsis,
n = 4; microangiopathy, n = 2), and hyperviscosity in 3 dogs (leish-
maniasis, n = 3). More than 1 indication was present in 7 dogs.
3.2 | Specifics of the mTPE treatments
Sixty-four mTPE treatments were performed with a median of 2 treat-
ments per dog (range, 1-3). Vascular access was provided with
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double-lumen central venous or hemodialysis catheters with diame-
ters (7-13.5 Fr) and lengths (16-28 cm) adapted to the dog's size.
Catheters included Arrow 7 Fr x 16 cm Blue FlexTip catheters in
4 dogs, Arrow 8 Fr x 20 cm in 13 dogs, Arrow 12 Fr x 20 cm in 4 dogs
(Teleflex Medical GmbH, Belp, Switzerland); Medcomp Duo-Flow 9 Fr
x 15 cm in 1 dog, Medcomp HemoCath 11.5 Fr x 20 cm in 6 dogs,
Medcomp 11.5 Fr x 24 cm in 2 dogs, Medcomp 13.5 Fr x 24 cm in
1 dog, and Medcomp 13.5 Fr x 28 cm in 3 dogs (Euromed Swiss AG,
Frauenfeld, Switzerland).
Nineteen mTPE treatments (30%) were combined sequentially
with intermittent hemodialysis in 15 dogs (44%) with acute kidney
injury (AKI). The mTPE procedure was performed first in all these
combined treatments with the exception of 1 mTPE treatment per-
formed after hemodialysis. The dogs were premedicated with diphen-
hydramine (1 mg/kg IV) for 14 treatments (22%), dexamethasone
(0.2 mg/kg IV) for 1 treatment (2%), and combined dexamethasone-
diphenhydramine for 1 treatment (2%). No premedication was admin-
istered for 48 treatments (75%).
The median PVE calculated for the treatment prescription was
742 mL (IQR, 453-1825), to reach a goal of 1.0 PVE per treatment.
The main characteristics of the mTPE treatments and the composition
of the replacement fluid are summarized in Table 1. Except for the
first 12 treatments in which HES was administered last and
5 treatments in which a change was deemed necessary, the order of
administration was typically starting with HAlb, continuing with HES
and saline, and finishing with FFP (n = 46). The dose of HAlb adminis-
tered was 0.64 g/kg (IQR, 0.44-0.85) but, as HAlb was typically adminis-
tered first (n = 60), approximately half of it can be estimated to have
been removed during the treatment. The average chloride concentra-
tion of the replacement fluid was 129 mmol/L (IQR, 123-138).
3.3 | Physiologic and metabolic response to mTPE
Body weight increased with mTPE a median of 180 g (IQR, 5-300),
corresponding to 1.5% (IQR, 0.1%-3.0%) of the initial weight
(P < .001). Body temperature did not change significantly, with a dif-
ference of +0.1C (−0.2 to 0.4, P = .29). Heart rate increased mildly
from 90 bpm (IQR, 69-116) to 109 bpm (IQR, 83-134, P < .001), and
systolic blood pressure increased mildly from 144 mm Hg (IQR,
130-156) to 154 mm Hg (IQR, 132-169, P = .02).
Complete blood counts were performed before and after mTPE
treatment in 4 dogs only. The most relevant change was a marked
decrease in the platelet count in all 4 dogs (median from 228 to
48 G/L), whereas packed cell volume did not change significantly. Rel-
evant changes in the CBC, chemistry profile, and coagulation variables
are summarized in Table 2. With the chosen composition of the
replacement fluid, total proteins decreased by 24.7% (IQR, 16.7-31.4;
P < .001), whereas serum albumin did not change significantly with a
reduction ratio of 5.1% (IQR, −10.8 to 12.5, P = .13). The azotemia
decreased significantly but only minimally with a median urea reduc-
tion ratio of 9.0% (IQR, 0.7-15.7; P < .001) and a creatinine reduction
ratio of 4.5% (IQR, −6.6 to 10.6; P = .006). For dogs with markedly
increased serum bilirubin pretreatment (>2.9 mg/dL, 50 μmol/L,
n = 11), the total bilirubin concentration decreased significantly with a
median reduction ratio of 36% (IQR, 13%-43%, P = .02). The only sig-
nificant change noted in the coagulation profile was a marked
decrease in fibrinogen concentration by 53% (IQR, −30 to 63; P = .009),
without relevant changes in the coagulation times. Only minimal
changes were noted in the acid-base variables, including significant but
non clinically relevant metabolic acidosis and acidemia (Table 3).
3.4 | Treatment complications
Complications were observed in 22/64 treatments (34%). One techni-
cal complication because of low blood flow rates in a small-sized dog
caused early discontinuation of the treatment, but all other treatments
could be performed to satisfaction and reached >90% of the plasma
exchange goal. The following complications were observed: vomiting
(7 treatments), hemorrhagic diarrhea (1), sneezing (2), urticaria (1), laryn-
geal edema (1), chemosis (1), system clotting (2), and technical problem
because of auto-test difficulties related to insufficiently low blood flow
rates (5). Two dogs developed progressive dyspnea after completion of
their treatments as a worsening of their preexisting leptospirosis-
associated pulmonary hemorrhages and were therefore euthanized.
Five of the 7 episodes of vomiting and the 2 episodes of sneezing
were observed during the second third of the plasma transfusions and
TABLE 1 Characteristics of 64 membrane-based therapeutic
plasma exchange (mTPE) treatments and composition of the
replacement fluid
Treatment characteristics
Total blood volume processed (mL) 6000 (3450-10 900)
(mL/kg) 432 (372-492)
Average blood flow rate (mL/min) 45 (30-70)
Average filtration fraction (%) 14 (12-15)
Volume of filtered plasma (mL) 726 (482-1801)
(mL/kg) 60 (54-67)
Plasma volume exchange 1.00 (0.94-1.04)
Duration of procedure (min) 125 (103-163)
Exchange rate (mL/min) 5.8 (4.3-8.9)
Composition of the replacement fluida
HAlb (59/63 tx, 94%) (%) 24% (17-29)
(mL/kg) 12.9 (8.9-17.0)
HES (20/63 tx, 32%) (%) 0% (0-10)
(mL/kg) 0 (0-5.7)
NaCl (40/63 tx, 63%) (%) 15% (0-46)
(mL/kg) 9.8 (0.0-26.7)
FFP (63/63 tx, 100%) (%) 48% (29-62)
(mL/kg) 25.2 (17.9-36.3)
Notes: Data are presented as median (interquartile range [IQR]). The fluids
used as replacement of plasma included human albumin (HAlb, 5%);
hydroxyethylstarch (HES, 3%); saline (NaCl, 0.9%); and fresh-frozen
plasma (FFP).
aData from 63 treatments. In 1 treatment, the exchange could not really
be started because of insufficient blood flow rate.
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they were associated with a low iCa of 0.5-0.7 mmol/L, concentrations
otherwise rarely seen (<10%) in these treatments. The dogs improved
rapidly after bolus injection of calcium gluconate. The observed transfu-
sion or allergic reactions with urticaria, laryngeal edema, and chemosis
occurred in 3 dogs that had not been premedicated. The fast resolution
after interruption of the plasma exchange and injection of dexametha-
sone and diphenhydramine allowed these treatments to be performed
to completion without further complication. These complications trig-
gered a change in our protocol, including the IV injection of 1 mg/kg
diphenhydramine, 10 minutes before treatment.
Clinical and laboratory signs suggestive of a reaction to the adminis-
tration of HAlb or HES were not observed during follow-up in any of
the dogs after TPE. The allergic and transfusion reactions mentioned
above recovered quickly and uneventfully after temporarily discontinuing
the plasma transfusion and administering antihistamines and steroids,
suggesting a reaction to FFP rather than to HAlb. The described pul-
monary hemorrhages were most likely unrelated to the infusion of
HAlb as they were already present before TPE in the affected dogs
with leptospirosis. Twelve dogs died before the 14-day follow-up could
be completed (median 2 days; IQR, 1-4). In all other dogs, the monitoring
could be completed as planned, either during their hospitalization (n = 6)
or at rechecks after their discharge from hospital (n = 16).
3.5 | Anticoagulation and citrate toxicosis
Three anticoagulation strategies were used in the mTPE treatments:
SH for 2 treatments (3%), RCA for 24 treatments (38%), and HepCit
for 38 treatments (59%). In the treatments with SH, a total of
148 IU/kg (IQR, 142-153) unfractionated heparin was administered,
corresponding to 63 IU/kg/h (IQR, 62-65). In HepCit combined
TABLE 3 Changes in acid-base related laboratory variables during the mTPE treatment. Venous blood gas parameters were measured before
treatment (pre-mTPE), during the phases of plasma replacement with HAlb, HES, NaCl, and FFP, respectively, and after treatment (post-mTPE)
RR Pre-mTPE HAlb HES NaCl FFP Post-mTPE
pH 7.33-7.51 7.40 (7.33-7.45) 7.41 (7.32-7.45) 7.34 (7.30-7.40) 7.42 (7.37-7.47) 7.40 (7.35-7.43) 7.37* (7.33-7.39)
pCO2 (mm Hg) 25.2-45.4 34.2 (31.3-38.3) 29.9 (26.5-32.6) 31.4 (29.4-31.6) 27.2 (21.4-31.0) 30.2 (27.6-33.5) 35.8 (32.7-39.1)
HCO3
− (mmol/L) 18.4-26.3 21.4 (19.7-23.1) 19.7 (16.0-21.2) 17.6 (16.5-19.1) 20.0 (15.2-22.0) 19.7 (18.0-21.1) 20.4* (18.5-22.0)
BE (mmol/L) −2.0 to +2.0 −3.4
(−5.8 to −1.4)
−5.6
(−10.6 to −3.6)
−8.1
(−9.6 to −6.2)
−5.0
(−11.1 to −2.6)
−5.3
(−7.4 to −3.4)
−4.5*
(−6.8 to −2.6)
AG (mmol/L) 10.8-19.3 14.1 (10.7-17.6) 16.7 (12.4-22.1) 17.5 (14.4-22.8) 14.5 (10.8-19.9) 17.5 (13.7-22.2) 16.4* (13.5-20.9)
Lactate (mmol/L) <2.0 1.3 (0.9-1.7) 1.2 (0.8-1.6) 1.7 (1.7-1.7) 2.1 (0.8-2.4) 1.4 (1.1-1.6) 1.5 (1.1-2.0)
Note: Data are presented as median (interquartile range [IQR]).
Abbreviations: AG, anion gap; BE, base excess; FFP, fresh-frozen plasma; HAlb, human albumin; HES, hydroxyethylstarch; mTPE, membrane-based
therapeutic plasma exchange; NaCl, saline; RR, reference range.
*P < .001, for paired comparison between pre- and post-mTPE with a Wilcoxon signed-rank test.
TABLE 2 Changes in laboratory
variables associated with mTPE
treatment
Variable n (pre/post) RR Pre-mTPE Post-mTPE P
PCV (%) 63/62 39-57 24.0 (18.3-27.0) 23.0 (19.3-28.8) <.001
PLT (103/μL) 30/4 150-400 134 (35-272) 48 (37-62) n/a
WBC (103/μL) 30/4 6.0-12.0 19.0 (12.7-29.8) 19.5 (16.1-24.4) n/a
Na (mmol/L) 64/63 142-154 144 (141-148) 151 (147-155) <.001
K (mmol/L) 64/63 4.22-5.43 3.8 (3.3-4.2) 3.3 (2.9-4.0) <.001
Urea (mg/dL) 63/63 19.8-64.9 65.5 (37.2-232.4) 54.1 (30.6-193.4) <.001
Crea (mg/dL) 64/63 0.6-1.3 0.8 (0.6-5.4) 0.9 (0.5-4.7) .006
Bili (mg/dL) 34/20 0.03-0.2 2.9 (0.6-17.9) 6.1 (1.0-12.9) n/a
TP (g/dL) 51/56 5.6-7.3 4.8 (4.1-5.9) 3.8 (3.1-4.6) .01
Alb (g/dL) 64/63 3.0-4.0 2.4 (2.0-2.7) 2.3 (2.1-2.5) .13
PT (s) 30/13 6.3-8.5 8.8 (7.9-9.6) 9.5 (8.8-9.9) n/a
aPTT (s) 30/13 9.6-16.1 13.4 (12.3-20.4) 14.9 (12.4-17.6) n/a
Fib (mg/dL) 30/13 150-300 276 (167-480) 139 (121-195) n/a
Notes: Data are presented as median (interquartile range [IQR]) and P reflects the statistical significance
tested with a Wilcoxon signed-rank test for paired data. Statistical analysis was only performed when
data were available for more than half of the treatments.
Abbreviations: Alb, albumin; aPTT, activated partial thromboplastin time; Bili, bilirubin; Crea, creatinine;
Fib, fibrinogen; K, potassium; mTPE, membrane-based therapeutic plasma exchange; Na, sodium; PCV,
packed cell volume; PLT, platelet count; PT, prothrombin time; RR, reference range; TP, total protein;
WBC, white blood cell count.
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anticoagulation, 53 IU/kg (IQR, 29-72) unfractionated heparin was
administered, corresponding to 20 IU/kg/h (IQR, 13-37).
For citrate anticoagulation, the total citrate load was 1.91 mmol/kg
(IQR, 1.57-2.27) and the average citrate administration rate was
14.6 μmol/kg/min (IQR, 11.1-19.6). The plasma administration contrib-
uted to 28% (IQR, 20%-35%) of the citrate load in these dogs. Based
on the established criteria for iCa monitoring, citrate infusion rate had
to be increased 58 times in 35/62 treatments (56%) and decreased
88 times in 49/62 treatments (79%). Calcium infusion rate had to be
increased 79 times in 40/62 treatments (65%) and decreased 64 times
in 42/62 treatments (68%).
The dogs showed evidence suggestive of citrate accumulation in
all treatments, with a decrease in iCa, an increase in niCa, an increase
in TCa, and an increase in the TCa:iCa ratio (Table 4 and Figure 1).
This citrate accumulation was classified as nonrelevant for 17 treat-
ments (27%), mild for 20 treatments (31%), and severe for 27 treat-
ments (42%). The citrate accumulation was associated with the total
citrate load, with 1.59 mmol/kg citrate (IQR, 1.43-1.96) for dogs with
nonrelevant accumulation, 1.78 mmol/kg (IQR, 1.49-2.21) for mild
accumulation, and 2.12 mmol/kg (IQR, 1.81-2.48) for severe accumu-
lation (P = .002). Corresponding citrate administration rates were 11.1
(IQR, 9.9-13.5), 12.0 (IQR, 9.4-17.4), and 17.7 μmol/kg/min (IQR,
14.4-21.9), respectively (P = .001). Based on the ROC curve analy-
sis, a citrate administration rate of >8.9 μmol/kg/min (citrate load
>1.30 mmol/kg) was associated with a >20% risk, and a rate of
>11.4 μmol/kg/min (citrate load >1.59 mmol/kg) with a >50% risk
of relevant citrate accumulation.
Dogs with renal impairment were approximately twice as likely to
show citrate accumulation as dogs with normal renal function, despite
similar total citrate loads and citrate administration rates (Table 5 and
Figure 2). Based on the ROC curve analysis, a total citrate administra-
tion rate of ≤5.5 μmol/kg/min (citrate load ≤0.74 mmol/kg) in dogs with
renal impairment or ≤9.0 μmol/kg/min (citrate load ≤1.43 mmol/kg) in
dogs with normal renal function carried ≤20% risk of severe citrate
accumulation. Dogs with impaired liver function and a serum bilirubin
concentration of >1.2 mg/dL (20 μmol/L) were not more likely to
develop citrate accumulation compared to dogs with a lower bilirubin
concentration (Table 5). In these dogs, impaired liver function was
defined as the presence of at least 2/5 abnormal liver function tests
(bilirubin, albumin, glucose, urea, and cholesterol) and at least
2-fold increased alanine aminotransferase (ALAT) and aspartate
aminotransferase (ASAT). Dogs with hemolytic anemia and
prehepatic hyperbilirubinemia were not included. Even more
severe hyperbilirubinemia (>5.8 mg/dL, 100 μmol/L) did not show
an increased prevalence of severe citrate accumulation, with 6/16
(38%). Similarly, the combination of renal and liver impairment was not
associated with an increased risk of citrate accumulation either.
Clinical problems associated with the anticoagulation procedures
included hemorrhagic complications (progression of leptospirosis-
associated pulmonary hemorrhages in 2 dogs and hemorrhagic diarrhea
in 1 dog), thrombotic complications (clotting of the filters in 5 treat-
ments: 2 treatments requiring a change of filter and 3 treatments
requiring a lower filtration fraction and an extension of the treatment
duration), and hypocalcemia-related complications (sneezing in 2 treat-
ments and vomiting in 5 treatments).
4 | DISCUSSION
Based on the results of the present retrospective study and consider-
ing the severity of the treated conditions, mTPE can be considered a
reasonably safe but not benign procedure for dogs. With a treatment
dose of 1 PVE and a combination or replacement fluids including
approximately 50% FFP combined with HES, HAlb, and NaCl as used in
the study, a stable serum albumin and a moderate decrease in serum
fibrinogen concentration can be expected. A substantial decrease in
serum bilirubin was however observed in dogs with markedly increased
values before treatment. As expected, electrolytes, venous blood gas,
and most biochemical variables remained stable, although more compli-
cations and changes could have been observed if complete bloodwork
had been performed systematically after all treatments.
All dogs treated with mTPE showed laboratory signs of citrate
accumulation from the RCA procedure and from the rapid FFP trans-
fusion. The observed laboratory changes indicating citrate accumula-
tion were however only rarely associated with mild clinical signs of
TABLE 4 Changes in calcium fractions and evidence of citrate
accumulation in dogs treated with mTPE
Variables Before tx After tx Δ
TCa (mg/dL) 9.4 (8.5-10.0) 14.9 (12.4-16.8) 5.1 (3.1-7.3)
TCa (mmol/L) 2.33 (2.12-2.50) 3.71 (3.09-4.20) 1.28 (0.77-1.83)
ΔTCa >0.0 mg/dL
>0.0 mmol/L
61/62 (98%)
>4.0 mg/dL
>1.0 mmol/L
39/62 (63%)
>6.0 mg/dL
>1.5 mmol/L
23/62 (39%)
iCa (mmol/L) 1.17 (1.08 to
1.26)
0.96 (0.85 to
1.10)
−0.21 (−0.28 to
−0.09)
ΔiCa <0.0 52/59 (88%)
<−0.2 30/59 (47%)
<−0.3 13/59 (22%)
niCa (mmol/L) 1.11 (1.00-1.30) 2.69 (2.14-3.27) 1.50 (0.91-1.92)
ΔniCa >0.0 57/57 (100%)
>1.0 39/57 (68%)
>1.5 28/57 (49%)
TCa:iCa ratio
(mmol/L:mmol/L)
1.93 (1.84-2.36) 3.70 (3.17-4.42) 1.72 (1.11-2.34)
ΔTCa:iCa >0.0 57/57 (100%)
>1.0 45/57 (79%)
>2.0 18/57 (32%)
Note: Descriptive statistics of the variables before and after the
treatments and their respective changes (Δ) are presented as median
(interquartile range [IQR]) and the proportions of treatments with the
corresponding changes as fractions (%).
Abbreviations: Δ, delta (difference); iCa, ionized calcium; niCa, non-ionized
calcium; TCa, total calcium; TCa:iCa ratio, total to ionized calcium ratio;
tx, treatment.
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hypocalcemia, such as sneezing in 2 dogs and vomiting in 5 dogs.
More severe signs commonly associated with hypocalcemia such as
facial rubbing, muscle cramping, or seizure-like activity were not
observed in these treatments. The higher citrate accumulation in dogs
with renal impairment suggests that dogs with normal renal function
likely excrete some of the excess citrate renally. An indirect effect of the
uremic state on citrate metabolism has not been reported in other spe-
cies and seems unlikely. An average total citrate administration rate of
≤5.5 μmol/kg/min in dogs with renal impairment or ≤9.0 μmol/kg/min in
dogs with normal renal function carried <20% risk of severe citrate accu-
mulation, and these rates should therefore be viewed as a suggestion for
safe RCA in dogs treated with mTPE.
Interestingly, although citrate is metabolized primarily in the liver,
even severe liver function impairment was not associated with an
increased risk of citrate accumulation. Similar total citrate loads
between dogs with and without liver failure suggest that this was not
F IGURE 1 Changes in A, ionized calcium; B, non-ionized calcium; C, total calcium; and D, total calcium to ionized calcium ratio with
membrane-based therapeutic plasma exchange (mTPE). The histograms represent the data before (green) and after (blue) mTPE treatment, as well
as their resulting changes (red). Widths of the categories are 0.1 mmol/L for iCa, 0.25 mmol/L for niCA, and 0.5 mmol/L for TCa and TCa:iCa. iCa,
ionized calcium; niCa, non-ionized calcium; TCa, total calcium; TCa:iCa, total calcium to ionized calcium ratio
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because of a particularly restrictive citrate administration or FFP
transfusion rates in the affected dogs. In a multicenter prospective
study looking at the safety of RCA in intensive human patients with
various degrees of liver failure, a sufficient cellular respiration was
suspected to be essential for the liver metabolism of citrate rather
than the degree of liver function per se.25 Various types of liver dis-
eases may therefore affect the capacity of hepatic citrate metabolism
differently.
Although one third of the treatments were associated with com-
plications, most of those were mild and self-limiting, and only 1 treat-
ment had to be discontinued early, not reaching its exchange target.
In that and 4 other treatments in very small-sized dogs, the required
minimal blood flow rate of 50 mL/min was not reached consistently,
causing difficulties with the mandatory auto-test of the machine,
emphasizing the need for a reliable large-bore venous access. Although
most cTPE platforms have larger extracorporeal circuit volumes than
mTPE platforms, they can function effectively with inlet blood flow
rates as low as 5 mL/min, which can be very helpful for small animals.
The allergic-type reactions with chemosis, urticaria, and laryngeal edema
observed in 3 dogs responded quickly to antihistamines and steroids.
Nevertheless, we decided to change our protocol and not to rely solely
on pretreatment test injections of the albumin solution and the individ-
ual plasma units, but also to include systematically a premedication
with intravenous diphenhydramine, 10 minutes before the treatment.
No allergic reaction was noted in the 22 treatments performed after this
change in our protocol. The two dogs with progressive dyspnea and
death following the completion of the procedure already had evidence
of severe pulmonary hemorrhages associated with leptospirosis and
this fatal outcome is unlikely to be because of the treatment itself.
Although both dogs have been treated without heparin, an exacerba-
tion of the bleeding associated with the decreased platelet count
resulting from the mTPE treatment can however not be ruled out. No
evidence of such exacerbation was noticed in 12 other dogs with active
leptospirosis-associated pulmonary hemorrhages. Similarly, no bleeding
complication was observed in dogs with severe immune-mediated
thrombocytopenia. Until this is evaluated prospectively, mTPE treat-
ments in dogs at high risk of bleeding should be planned cautiously,
carefully weighing the risks and benefits for the animals and avoiding
the use of SH.
The choice of replacement fluid is complex and guided mostly by
the clinical condition, and also by resource availability and financial
concerns. The theoretically ideal replacement with 100% FFP is often
cost-prohibitive, especially in repeated treatments in large-sized dogs.
A full FFP replacement also brings some concerns, including transmis-
sion of undiagnosed infectious diseases in an often immunocompro-
mised animal and a high load of citrate limiting the possible plasma
exchange rate and prolonging the treatments. In humans, replacement
with 100% FFP is also rare and it is reserved for specific conditions.
TABLE 5 Citrate accumulation in dogs with renal or hepatic function impairment treated with mTPE
Variables Not affected Affected P
Renal n = 38 n = 26
Total citrate load (mmol/kg) 1.80 (1.56-2.25) 1.99 (1.53-2.25) .61
Citrate rate (μmol/kg/min) 13.8 (10.1-19.4) 15.1 (11.1-18.5) .73
Prevalence of all levels CitAcc 24/38 (63%) 23/26 (88%) .04
Prevalence of severe CitAcc 10/38 (26%) 17/26 (65%) .004
OR for all levels CitAcc - 2.11 (1.07-4.20) .03
OR for severe CitAcc - 2.30 (1.34-3.95) .002
Hepatic n = 15 n = 19
Total citrate load (mmol/kg) 1.86 (1.76-2.24) 1.95 (1.62-2.27) .84
Citrate rate (μmol/kg/min) 14.0 (10.7-17.0) 14.3 (10.0-17.2) .86
Prevalence of all levels CitAcc 9/15 (60%) 16/19 (84%) .14
Prevalence of severe CitAcc 7/15 (47%) 7/19 (37%) .73
OR for all levels CitAcc - 1.84 (0.84-4.21) .12
OR for severe CitAcc - 0.81 (0.41-1.63) .56
Renal and Hepatic n = 22 n = 12
Total citrate load (mmol/kg) 1.95 (1.75-2.37) 1.86 (1.49-2.08) .35
Citrate rate (μmol/kg/min) 13.0 (10.1-16.3) 15.1 (9.5-18.2) .65
Prevalence of all levels CitAcc 15/22 (68%) 10/12 (83%) .44
Prevalence of severe CitAcc 9/22 (41%) 5/12 (42%) 1.00
OR for all levels CitAcc - 1.57 (0.78-3.17) .20
OR for severe CitAcc - 1.02 (0.50-2.07) .97
Note: Numerical data are presented as median (interquartile range [IQR]) and prevalence rates as proportions and fractions (%).
Abbreviations: CitAcc, citrate accumulation; mTPE, membrane-based therapeutic plasma exchange; OR, odds ratio.
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The ideal replacement solution in dogs is unknown at this time. The
data reported in the present study therefore bring an important basis
for a more differentiated choice of replacement fluid, showing that a
50% FFP replacement does not lead to relevant alterations in the
coagulation profiles and therefore can be considered in animals with-
out severe underlying hemostatic disturbances. The inclusion of HES
and HAlb was not visibly associated with adverse effects despite the
increasing concerns with these solutions potentially associated with the
development of AKI26,27 and Type III hypersensitivity reactions,28,29
respectively. Neither hospital-acquired AKI nor progressive proteinuria
could be detected in these dogs during hospitalization or follow-up.
However, as not all dogs could be monitored for at least 14 days fol-
lowing administration of HAlb and HES, caution is warranted until the
safety of these solutions is better characterized in animals and a sys-
tematic long-term follow-up should be implemented in dogs receiving
these solutions for this or other indications. In the meantime, we
decided to minimize the use of these solutions. Human albumin was
administered first for transient support of the oncotic pressure, estimat-
ing that approximately half of it would be removed in the later phase of
the treatment. Hydroxyethylstarch was used only if deemed necessary
to support vascular volume and blood pressure. Fresh-frozen plasma
was always administered last to minimize its fraction directly filtered
out and lost during the rest of the treatment. Another commonly used
replacement fluid prescription is 25% HES, 25% saline, 50% FFP, in that
order to avoid the potential risk of HAlb administration. Despite
concerns linked to the use of high chloride fluids in dogs with renal
impairment, we added saline to our replacement fluid. Calculated
average chloride concentration of the pooled replacement fluid was
129 mmol/L. Although saline was only a small part of the replacement
fluid, changing it to a lower chloride crystalloid could have decreased
this chloride load by approximately 14 mmol/L. Definitive recommen-
dations can certainly not be drawn from the present retrospective
study, but the data collected should be used to design prospective
studies with specific TPE indications.
The main limitations of the present study include its retrospec-
tive nature, even if most data have been collected prospectively and
protocols defined in advance. Some of the nonessential laboratory
analyses thus were not performed in all dogs. The study results
should therefore be considered descriptive and viewed as a step in
the development of this important modality in small animals.30 The
wide variety of indications and underlying medical conditions repre-
sent another limitation, but since the goals of the study were to
describe the technical aspects of the treatment, these features add
valuable information for situations that are encountered with clinical
cases and the conclusions concerning difficulties and complications
can be expanded to a wide range of dogs and conditions. The analy-
sis of the effects of kidney and liver involvement on the citrate toler-
ance should be viewed as an attempt to define medical conditions
possibly associated with an increased risk of citrate accumulation.
Although a definitive statement on the safety of RCA for mTPE in
F IGURE 2 Difference in the relationship of citrate administration to citrate accumulation for dogs with and without renal impairment. The
membrane-based therapeutic plasma exchange (mTPE)-associated increase of A, non-ionized calcium (niCa) concentration and B, the post-mTPE
total to ionized calcium (TCa:iCa) ratio are presented and stratified for dogs based on their renal function. The scatter plots represent the data and
the regression lines of treatments from dogs with normal renal function (black diamonds, solid line) and from dogs with renal impairment (open
circles, dotted line). The citrate administration rate includes both citrate administered for anticoagulation and citrate contained in fresh frozen
plasma. The regression analysis denoted weak significant associations only for dogs with normal renal function (niCa: r2 = .21; P = .008;
posttreatment TCa:iCa ratio: r2 = .46; P < .001). The associations were however not significant for dogs with impaired renal function (niCa:
r2 = .08; P = .17; posttreatment TCa:iCa ratio: r2 = .07; P = .22)
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dogs with renal or hepatic involvement would require a prospective
evaluation of a larger number of dogs with various pathomechanisms
and more thorough functional evaluation, the results of the present
study suggest that RCA can be used for most disease conditions
resulting in renal or liver failure, if necessary with individual adapta-
tions of the citrate administration rates.
In conclusion, we described in the present study the technique of
mTPE in dogs with various diseases and we reported the expected
changes in physiological and laboratory variables. We further deter-
mined tentative rates of safe citrate administration for dogs with and
without renal impairment, allowing this technique to be used in dogs
at risk of bleeding. Altogether this procedure can be performed safely
in most dogs even with multiple and severe organ impairment, pro-
vided that a close monitoring of the TCa and iCa can be performed.
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